Table 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study
收藏数据链接：
官方服务：
资源简介：
Baseline demographic and clinical characteristics.
创建时间：
2025-11-03
